Evidence map›Paper›PMID 39904835›Full record

ArticleHuman cell2025

Establishment and characterization of NCC-SFT1-C1: a novel patient-derived cell line of solitary fibrous tumor.

Shuhei Iwata, Rei Noguchi, Julia Oosaki, Yuki Adachi, Yomogi Shiota, Eisuke Kobayashi, Toshiyuki Takemori, Shogo Nishino, Akihiko Yoshida, Seiji Ohtori and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shuhei IwataDivision of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Rei NoguchiDivision of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Julia OosakiDivision of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yuki AdachiDivision of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Yomogi ShiotaDivision of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Eisuke KobayashiDepartment of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Toshiyuki TakemoriDepartment of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Shogo NishinoDepartment of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Akihiko YoshidaDepartment of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Seiji OhtoriDepartment of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Akira KawaiDepartment of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Tadashi KondoDivision of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. proteomebioinformatics@gmail.com.ORCID http://orcid.org/0000-0001-6405-7792

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solitary fibrous tumors (SFTs) are rare mesenchymal tumors characterized by recurrent NAB2::STAT6 gene fusion, which are associated with an unpredictable clinical course, including the potential for recurrence or metastasis. Current therapeutic approaches for relapsed cases remain ineffective, and there is no established standard of care for SFTs. Although patient-derived cancer cell lines are fundamental research tools, only a few cell lines have been developed for SFTs. To address this, we established a novel SFT cell line, NCC-SFT1-C1, derived from surgically resected tumor tissues of a patient with SFT. The cell line retains the characteristic recurrent NAB2::STAT6 gene fusion in concordance with the matched original tumor. These cells exhibit moderate proliferation, invasion ability, and spheroid formation. We demonstrated that NCC-SFT1-C1 cells are useful for the high-throughput screening of the antiproliferative effects of 221 oncology drugs. Therefore, the NCC-SFT1-C1 cell line is a valuable tool for basic and preclinical studies on SFT.

Indexed as

Solitary Fibrous TumorsCell Line, TumorCell ProliferationGene FusionHumansNeoplasm InvasivenessRepressor ProteinsSpheroids, CellularSTAT6 Transcription FactorNAB2 protein, humanRepressor ProteinsSTAT6 protein, humanSTAT6 Transcription FactorDrug screeningPatient-derived cancer modelPatient-derived cell lineSarcomaSolitary fibrous tumor

Identifiers

PMID39904835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.